SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND). Investors who purchased or otherwise acquired shares between November 9, 2015 and November 14, 2016 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the January 17, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at, or by email at

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The complaint alleges that during the Class Period, Ligand made false and/or misleading statements and/or failed to disclose: that Ligand overstated the value of certain Deferred Tax Assets by about $27.5 million or 13%; that the Company's outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; that Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; that the Company lacked effective internal control over financial reporting; and that as a result of the above, Ligand's statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this news was announced, shares of Ligand fell in value, causing investors harm.

If you liked this article you might like

6 Stocks with Unusual Volume Activity

6 Stocks on the Move With Unusual Volume

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More